Finally, a recent retrospective study, including 94 all-stage cHL patients undergoing a first-line therapy, demonstrated that the highly recurrent XPO1 E571K mutation is present in one-quarter of classical Hodgkin’s lymphoma patients [16]. This evidence concerns the gene XPO1 and classic Hodgkin lymphoma.